Glooko announced today that it entered into a partnership with Sanofi to integrate a connected device for insulin pens into its digital platform. SoloSmart, a single-piece, add-on connected device works with Sanofi’s SoloStar and DoubleStar insulin injection pens. It records the insulin dose, date and time of injection. Through this partnership, the company’s can offer […]
Diabetes
Tandem Diabetes Care stock down on Q4 misses
Tandem Diabetes Care (Nasdaq:TNDM) shares are down today on fourth-quarter results that came up shy of the consensus forecast. Shares of TNDM were down more than 6% to $37.28 apiece by midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 8%. Yesterday evening, the […]
Innovation Zed wins CE mark for insulin pen add-on device
Innovation Zed announced that it received CE mark approval in Europe for its InsulCheck Dose add-on device. Dublin, Ireland-based Innovation Zed designed the InsulCheck Dose device as a single-unit add-on device for pen injectors. It automatically captures dose value dialed, injection event time stamps and temperature. The device also captures mounting and unmounting events. According […]
DiabetesWise launches Prescription Tool to help providers pick devices for patients
DiabetesWise announced today that it launched its advanced Prescription Tool for the DiabetesWise Pro website. In April 2022, the company launched its DiabetesWise Pro website to help providers make informed decisions on diabetes devices. The easy-to-use and free tool offers access in the clinical practice or at the point of care. Providers can identify the […]
Ascensia partners with Snaq on diabetes management
Ascensia Diabetes Care announced today that it entered into a global collaboration with diabetes management company Snaq. Snaq develops an app-based solution offering insights on food and nutrition for people with diabetes. Ascensia develops the Controu blood glucose monitoring system and distributes Senseonics’ Eversense CGM systems. The companies plan to integrate technologies to help with […]
EOFlow invests $7.7B in Pharmeo subsidiary for non-insulin drug delivery development
EOFlow announced today that it plans to invest $7.7 billion (9.9 billion Korean Won) in its wholly-owned Pharmeo subsidiary. The investment aims to advance R&D and commercialization of non-insulin drugs with EOFlow’s wearable drug delivery system. EOFlow intends to finance this investment through paid-in capital increase for the subsidiary. EOFlow owes the actual investment, totaling […]
Embecta stock soars on Street-beating Q4, raised 2023 guidance
Embecta (Nasdaq:EMBC) shares received a boost today on fourth-quarter results that came in well ahead of the consensus forecast. Shares of EMBC ticked up 7.9% at $30.67 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 11.3%. Wall Street’s positive reaction to […]
Insulet acquires assets of Automated Glucose Control for $25M
Insulet (Nasdaq:PODD) announced today that it acquired the assets of Automated Glucose Control, a developer of insulin delivery technology. This marks the second asset buy in as many days for Insulet. Yesterday, the company picked up automated insulin delivery patents from Bigfoot Biomedical. Both acquisitions cost the company $25 million. Palo Alto, California-based Automated Glucose Control […]
Medicare to cover Dexcom G7 when it launches this week
Dexcom (Nasdaq:DXCM) announced today that Medicare offers coverage for its beneficiaries using the next-generation G7 CGM. The company announced the coming U.S. launch for G7 in a Super Bowl Commercial with musician Nick Jonas last night. It’s slated to roll out on Friday, Feb. 17. San Diego-based Dexcom met the category requirements for therapeutic continuous […]
Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
Insulet (Nasdaq:PODD) announced today that it acquired assets related to Bigfoot Biomedical’s pump-based automated insulin delivery technologies. Acton, Massachusetts-based Insulet paid $25 million to acquire the AID assets. These include certain Bigfoot patents related to pumps that may be used for AID therapy. Insulet already develops its own AID technology with its Omnipod platform. The […]